Abstract
Background: Detection of neuroendocrine tumor (NET) disease progression is a key issue in determining management. Currently, assessment is by imaging (MRI/CT and Octreoscan®) and plasma Chromogranin A (CgA) measurement.Case presentation: We report use of a NET-specific multigene PCR-derived blood transcript signature (NET Index) to assess disease and correlated CgA and gene transcripts with MRI, CT, Octreoscan®, 11C-5HTP-PET/CT and 68Ga-DOTA-PET/CT in a patient with NET.Conclusions: Our results identify limitations in evaluating disease status by CgA and identify that a PCR-based test is more sensitive. Alteration in NET blood gene transcript levels prior to image-based tumor confirmation suggests this parameter may also have utility as an index of therapeutic efficacy.
Original language | English |
---|---|
Article number | 564 |
Journal | BMC Cancer |
Volume | 14 |
Issue number | 1 |
DOIs | |
Publication status | Published - Aug 5 2014 |
Keywords
- Gallium
- Biomarker
- Blood
- Carcinoid
- Chromogranin A
- Gene marker
- Neuroendocrine tumor
- PCR
- PET/CT
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Genetics
- Medicine(all)